Claudia Campanella

Dr. Claudia Campanella


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Celeste Caruso BavisottoCeleste Caruso Bavisotto
Celeste Caruso Bavisotto
Federica ScaliaFederica Scalia
Federica Scalia
Antonella Marino GammazzaAntonella Marino Gammazza
Antonella Marino Gammazza
DCDaniela Carlisi
Daniela Carlisi
FBFabio Bucchieri
Fabio Bucchieri
CCClaudia Campanella
Claudia Campanella
Extracellular vesicles (EVs), including exosomes, are membranous particles released by cells into the extracellular space. They are involved in cell differentiation, tissue homeostasis, and organ remodelling in virtually all tissues, including the central nervous system (CNS). They are secreted by a range of cell types and via blood reaching other cells whose functioning they can modify because they transport and deliver active molecules, such as proteins of various types and functions, lipids, DNA, and miRNAs. Since they are relatively easy to isolate, exosomes can be characterized, and their composition elucidated and manipulated by bioengineering techniques. Consequently, exosomes appear as promising theranostics elements, applicable to accurately diagnosing pathological conditions, and assessing prognosis and response to treatment in a variety of disorders. Likewise, the characteristics and manageability of exosomes make them potential candidates for delivering selected molecules, e.g., therapeutic drugs, to specific target tissues. All these possible applications are pertinent to research in neurophysiology, as well as to the study of neurological disorders, including CNS tumors, and autoimmune and neurodegenerative diseases. In this brief review, we discuss what is known about the role and potential future applications of exosomes in the nervous system and its diseases, focusing on cell–cell communication in physiology and pathology.

Verified
Journal Article
Open access
PDF file
CCClaudia Campanella
Claudia Campanella
Celeste Caruso BavisottoCeleste Caruso Bavisotto
Celeste Caruso Bavisotto
MLMariantonia Logozzi
Mariantonia Logozzi
Antonella Marino GammazzaAntonella Marino Gammazza
Antonella Marino Gammazza
DMDavide Mizzoni
Davide Mizzoni
Stefano FaisStefano Fais
Stefano Fais
Extracellular vesicles (EVs) are lipid membrane vesicles released by all human cells and are widely recognized to be involved in many cellular processes, both in physiological and pathological conditions. They are mediators of cell-cell communication, at both paracrine and systemic levels, and therefore they are active players in cell differentiation, tissue homeostasis, and organ remodeling. Due to their ability to serve as a cargo for proteins, lipids, and nucleic acids, which often reflects the cellular source, they should be considered the future of the natural nanodelivery of bio-compounds. To date, natural nanovesicles, such as exosomes, have been shown to represent a source of disease biomarkers and have high potential benefits in regenerative medicine. Indeed, they deliver both chemical and bio-molecules in a way that within exosomes drugs are more effective that in their exosome-free form. Thus, to date, we know that exosomes are shuttle disease biomarkers and probably the most effective way to deliver therapeutic molecules within target cells. However, we do not know exactly which exosomes may be used in therapy in avoiding side effects as well. In regenerative medicine, it will be ideal to use autologous exosomes, but it seems not ideal to use plasma-derived exosomes, as they may contain potentially dangerous molecules. Here, we want to present and discuss a contradictory relatively unmet issue that is the lack of a general agreement on the choice for the source of extracellular vesicles for therapeutic use.

1 May 2017 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
Celeste Caruso BavisottoCeleste Caruso Bavisotto
Celeste Caruso Bavisotto
DNDragana Nikolic
Dragana Nikolic
AGAntonella Marino Gammazza
Antonella Marino Gammazza
RBRosario Barone
Rosario Barone
FCFilippa Lo Cascio
Filippa Lo Cascio
CCClaudia Campanella
Claudia Campanella

10 April 2019 in Cancers
Verified
Journal Article
Open access
PDF file
CCCesare Cernigliaro
Cesare Cernigliaro
Antonella D'AnneoAntonella D'Anneo
Antonella D'Anneo
DCDaniela Carlisi
Daniela Carlisi
MGMichela Giuliano
Michela Giuliano
Antonella Marino GammazzaAntonella Marino Gammazza
Antonella Marino Gammazza
Marianna LauricellaMarianna Lauricella
Marianna Lauricella
Epidemiological studies suggest that chronic alcohol consumption is a lifestyle risk factor strongly associated with colorectal cancer development and progression. The aim of the present study was to examine the effect of ethanol (EtOH) on survival and progression of three different colon cancer cell lines (HCT116, HT29, and Caco-2). Our data showed that EtOH induces oxidative and endoplasmic reticulum (ER) stress, as demonstrated by reactive oxygen species (ROS) and ER stress markers Grp78, ATF6, PERK and, CHOP increase. Moreover, EtOH triggers an autophagic response which is accompanied by the upregulation of beclin, LC3-II, ATG7, and p62 proteins. The addition of the antioxidant N-acetylcysteine significantly prevents autophagy, suggesting that autophagy is triggered by oxidative stress as a prosurvival response. EtOH treatment also upregulates the antioxidant enzymes SOD, catalase, and heme oxygenase (HO-1) and promotes the nuclear translocation of both Nrf2 and HO-1. Interestingly, EtOH also upregulates the levels of matrix metalloproteases (MMP2 and MMP9) and VEGF. Nrf2 silencing or preventing HO-1 nuclear translocation by the protease inhibitor E64d abrogates the EtOH-induced increase in the antioxidant enzyme levels as well as the migration markers. Taken together, our results suggest that EtOH mediates both the activation of Nrf2 and HO-1 to sustain colon cancer cell survival, thus leading to the acquisition of a more aggressive phenotype.

Verified
Journal Article
Open access
PDF file
Celeste Caruso BavisottoCeleste Caruso Bavisotto
Celeste Caruso Bavisotto
Antonella Marino GammazzaAntonella Marino Gammazza
Antonella Marino Gammazza
FCFilippa Lo Cascio
Filippa Lo Cascio
EMEmanuele Mocciaro
Emanuele Mocciaro
AVAlessandra Maria Vitale
Alessandra Maria Vitale
Antonio Palumbo PiccionelloAntonio Palumbo Piccionello
Antonio Palumbo Piccionello
The fundamental challenge in fighting cancer is the development of protective agents able to interfere with the classical pathways of malignant transformation, such as extracellular matrix remodeling, epithelial–mesenchymal transition and, alteration of protein homeostasis. In the tumors of the brain, proteotoxic stress represents one of the main triggering agents for cell transformation. Curcumin is a natural compound with anti-inflammatory and anti-cancer properties with promising potential for the development of therapeutic drugs for the treatment of cancer as well as neurodegenerative diseases. Among the mediators of cancer development, HSP60 is a key factor for the maintenance of protein homeostasis and cell survival. High HSP60 levels were correlated, in particular, with cancer development and progression, and for this reason, we investigated the ability of curcumin to affect HSP60 expression, localization, and post-translational modifications using a neuroblastoma cell line. We have also looked at the ability of curcumin to interfere with the HSP60/HSP10 folding machinery. The cells were treated with 6, 12.5, and 25 µM of curcumin for 24 h, and the flow cytometry analysis showed that the compound induced apoptosis in a dose-dependent manner with a higher percentage of apoptotic cells at 25 µM. This dose of curcumin-induced a decrease in HSP60 protein levels and an upregulation of HSP60 mRNA expression. Moreover, 25 µM of curcumin reduced HSP60 ubiquitination and nitration, and the chaperonin levels were higher in the culture media compared with the untreated cells. Furthermore, curcumin at the same dose was able to favor HSP60 folding activity. The reduction of HSP60 levels, together with the increase in its folding activity and the secretion in the media led to the supposition that curcumin might interfere with cancer progression with a protective mechanism involving the chaperonin.

14 June 2018 in Brain Sciences
Verified
Journal Article
Open access
PDF file
FGFrancesca Graziano
Francesca Graziano
Celeste Caruso BavisottoCeleste Caruso Bavisotto
Celeste Caruso Bavisotto
Antonella Marino GammazzaAntonella Marino Gammazza
Antonella Marino Gammazza
Francesca RappaFrancesca Rappa
Francesca Rappa
EMEverly Conway de Macario
Everly Conway de Macario
GLGerardo Lacopino
Gerardo Lacopino
The European Organization for Research and Treatment of Cancer/National Cancer Institute of Canada Phase III trial has validated as a current regimen for high-grade gliomas (HGG) a maximal safe surgical resection followed by radiotherapy with concurrent temozolamide. However, it is essential to balance maximal tumor resection with preservation of the patient’s neurological functions. Important developments in the fields of pre-operative and intra-operative neuro-imaging and neuro-monitoring have ameliorated the survival rate and the quality of life for patients affected by HGG. Moreover, even though the natural history remains extremely poor, advancement in the molecular and genetic fields have opened up new potential frontiers in the management of this devastating brain disease. In this review, we aim to present a comprehensive account of the main current pre-operative, intra-operative and molecular approaches to HGG with particular attention to specific chaperones, also called heat shock proteins (Hsps), which represent potential novel biomarkers to detect and follow up HGG, and could also be therapeutic agents.